human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)

Award NoticeAwarded

This federal contract opportunity has been awarded to on May 29, 2025.

Award Information

This solicitation resulted in an award to for approximately $2,000,000 on May 29, 2025. Similar contracts are typically issued by DEPT OF DEFENSE under 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Award Number: HT9425-25-D-0009
Award Amount: $2,000,000
Award Date: May 29, 2025

View full award details on USASpending.gov

Key Takeaways

No response deadline specified - contact the agency for details
Full and open competition - all businesses eligible to bid
Work to be performed in FORT DETRICK, MD
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

Contract Details

Notice ID: HT9425-25-D-0009
Opportunity Type: Award Notice
Agency: DEPT OF DEFENSE
Sub-Agency: DEFENSE HEALTH AGENCY (DHA)
Office: ARMY MED RES ACQ ACTIVITY
Posted Date: Wednesday, June 4, 2025
Response Deadline: Not specified
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
PSC Code: 6550
Set-Aside: Full & Open Competition
Place of Performance: FORT DETRICK, MD, 21702
Status: Active

View on SAM.gov

Description

Mapp Biopharmaceutical, Inc. received a Firm Fix Price Sole Source IDIQ award for the delivery of human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags) in support of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).